ClinicalTrials.gg
Active, not recruitingNCT06023862DOVEUpdated Nov 18, 2026

A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)

A Phase 2 interventional study of Dostarlimab and Bevacizumab in Ovarian Neoplasms, Endometrial Neoplasms and Uterine Cervical Neoplasms, sponsored by Yonsei University. Active, not recruiting at 27 sites in 7 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Yonsei University · Phase 2, Interventional, and Treatment

How we know · 8 judgments

Updated Nov 18, 2026Now Active, not recruitingEnrollment updated+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
199
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 106 studies testing bevacizumab in Ovarian Neoplasms — 22 open to participants now, 32 under way, 9 of them phase 3. Bevacizumab · Ovarian Neoplasms.

Enrollment
23rd of 106
199 · median 52
Started
2024
with 3 others
Phase 2
66 of 106
11 open now
Primary completion
2027-08
later than 15 of 31 live
Registered
86th of 106
by date

Among the 106 studies testing bevacizumab in Ovarian Neoplasms, this one is the 23rd largest by enrollment, is one of 4 that started in 2024, is one of 66 in phase 2, reaches primary completion later than 15 of the 31 other live ones, and was the 86th registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

22 of the 106 studies testing bevacizumab in Ovarian Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies testing bevacizumab in Ovarian Neoplasms, or all of them as a file.
02

Study summary

Multicenter, randomized, open-label, phase II clinical study comparing Dostarlimab +/- Bevacizumab with standard chemotherapy in patients with gynecological clear cell carcinoma.

198 subjects will be enrolled in this study and will be assigned to three groups in a 1:1:1 ratio.

  1. Group A: Dostarlimab monotherapy

    • First 3 cycles: Dostalimab 500mg every 3 weeks, IV
    • 4 cycles \~ up to 24 months: Dostalimab 1000mg every 6 weeks, IV
  2. Group B: Dostarlimab + Bevacizumab combination therapy

    • First 3 cycles: Dostalimab 500mg every 3 weeks, IV
    • 4 cycles \~ up to 24 months: Dostalimab 1000mg every 6 weeks, IV
    • Bevacizumab administered IV at 15 mg/kg every 3 weeks until disease progression or unacceptable toxicity
  3. Group C: General chemotherapy (one of Pegylated liposomal doxorubicin, Doxorubicin, Paclitaxel, and Gemcitabine)
03

Conditions studied

  • Ovarian Neoplasms
  • Endometrial Neoplasms
  • Uterine Cervical Neoplasms
  • Vulvar Cancer
  • Vagina Neoplasm
  • Clear Cell Carcinoma
04

Who can participate

The criteria were revised on the registry on Nov 18, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

[Inclusion Criteria]

  1. Female patient is at least 18 years of age,
  2. Patient has signed the (ICF) and is able to comply with protocol requirements.
  3. Patient with proven confirmed recurrent or persistent clear cell carcinoma of the ovary, endometrium, cervix, vagina, and vulva

    • Local review by gynecologic pathologist required

      -≥50% clear cell histology in case of mixed carcinoma

    • WT-1 neg (Only in case of ovarian cancer) Note: In the case of including non-ovarian clear cell carcinoma with more than 20 cases, the decision is made through discussion with the SPONSOR.
  4. Patient with an (ECOG) performance status score of 0 or 1.
  5. Disease progression within 12 months of completing platinum-based chemotherapy
  6. 1-5 Notes: Patients can participate in the trial regardless of prior exposure to bevacizumab. The sponsor may limit the enrollment of patients with prior exposure to bevacizumab in order to ensure an appropriate representativeness (approximately 50%) of patients without prior exposure to bevacizumab.
  7. Patient with according 1.1 criteria
  8. Availability of Tumor tissue for translational research .

    -A formalin-fixed paraffin-embedded (FFPE) tumor block(preferred) or at least 23 slides (unstained, freshly cut, serial sections) must be submitted.

  9. Patients who consent to fresh tumor

    -Confirmed with at least one lesion with location accessible to safely biopsy per the clinical judgement of the investigator Note: If mandatory biopsies cannot be performed as per investigator's clinical judgement, discussion and agreement between investigator and Sponsor are required.

  10. Patient has adequate organ function, defined as follows:

    1. ≥ 1,500 cells/μL
    2. ≥ 100,000 cells/μL
    3. ≥ 9 g/dL or ≥ 5.6 mmol/L
    4. Serum creatinine ≤ 1.5× (ULN) or calculated ≥ 50 mL/min using the Cockcroft-Gault equation for patients with creatinine levels > 1.5× institutional ULN
    5. Total ≤ 1.5× ULN (≤ 2.0 x ULN in patients with known Gilbert's syndrome) or direct bilirubin ≤ 1× ULN
    6. (AST) and alanine aminotransferase (ALT) ≤ 2.5× ULN unless liver are present, in which case they must be ≤ 5× ULN
    7. or prothrombin time (PT) ≤1.5× ULN and activated partial thromboplastin time ≤1.5× ULN.Participants taking anticoagulants may be included on a stable dose with a therapeutic INR \<3.5. .
  11. Patient must have a negative serum pregnancy test within 72 hours of the first dose of study medication, unless they are of non-. If a negative result cannot be confirmed by a urine test, a serum pregnancy test is required. Non-childbearing potential is defined as follows:

    1. Patient is ≥ 45 years of age and has not had menses for > 1 year.
    2. A follicle-stimulating hormone value in the range upon screening evaluation if amenorrhoeic for \< 2 years without a hysterectomy and oophorectomy.
    3. Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation:

      • Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound, MRI, or CT scan.
      • Tubal ligation must be confirmed with medical records of the actual procedure.
      • Information must be captured appropriately within the site's source documents.
  12. Patient of childbearing potential must agree to use a highly effective method of with their partners starting from time of consent through 180 days after the last dose of study treatment.

Note: Abstinence is acceptable if this is the established and preferred contraception for the patient (Information must be captured appropriately within the site's source documents).

[Exclusion Criteria]

Patients are to be excluded from the study if they meet any of the following criteria:

  1. Patient has had ≥ 6 prior lines of chemotherapy. Surgery of the recurrence is allowed.
  2. Patient has received prior therapy with an , anti-PD-L1, or anti-PD-L2 agent.
  3. Patient has received prior anticancer therapy (chemotherapy, targeted therapies, hormonal therapy, radiotherapy) within 21 days or \< 5 times the half-life of the most recent therapy prior to Study Day 1, whichever is shorter.

    Note: Palliative radiation therapy to a small field ≥ 1 week prior to Day 1 of study treatment may be allowed after discussion with the SPONSOR.

  4. Patient with to chemotherapy or immune checkpoint inhibitor treatments or anti-angiogenic inhibitor
  5. Patients with uncontrolled hypertension (defined as systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥100 mmHg) based on an average of ≥ 3 BP readings on ≥ 2 sessions.
  6. Patients with evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
  7. Patients with current abdominal/pelvic fistula
  8. Patient has a concomitant , or patient has a prior non-gynecological malignancy who has been disease-free for \< 3 years or who received any active treatment in the last 3 years for that malignancy. Non-melanoma skin cancer is allowed.
  9. Patient has known uncontrolled central nervous system metastases, carcinomatosis meningitis, or both.

    Note: Patients with previously treated may participate provided they are stable (without evidence of disease progression by imaging [using the identical imaging modality for each assessment, either MRI or CT scan] for at least 4 weeks prior to the first dose of study treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and have not been using for at least 7 days prior to study treatment. Carcinomatous meningitis precludes a patient from study participation regardless of clinical stability.

  10. Patient has a known history of (HIV; HIV ½ antibodies). Participants with known human immunodeficiency virus(HIV) are allowed if they meet all of the following criteria:

    • Cluster of differentiation 4(CD4) ≥350/μL and viral load \<50 copies/mL.
    • No history of acquired immunodeficiency syndrome-defining opportunistic infections within 12 months before enrollment.
    • No history of HIV-associated malignancy for the past 5 years.
    • Concurrent antiretroviral therapy as per the most current National Institutes of Health (NIH) Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV started >4 weeks before study enrollment.
  11. Patient with presence of surface antigen or a positive antibody test result at screening or within 3 months before first dose of dostarlimab treatment.

    • Participants who are hepatitis B surface antigen positive may be enrolled if their HBV-DNA level is below the institutional lower limit.
    • Participants with chronic hepatitis B virus (HBV) infection who meet the criteria for anti-HBV therapy may be eligible if the participant is on a suppressive antiviral therapy before initiation of cancer therapy.
    • Participants with positive hepatitis C antibody due to prior resolved disease can be enrolled only if a confirmatory negative hepatitis C RNA polymerase chain reaction is obtained. Hepatitis C participants may be eligible if they both have completed curative therapy and have a hepatitis C viral load \<quantifiable limit.
  12. Patient has an active disease that has required systemic treatment in the past 2 years. Replacement therapy is not considered a form of systemic therapy (e.g., thyroid hormone or insulin).
  13. Patient has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of systemic therapy within 7 days prior to the first dose of study treatment. Patients who have received acute and/or low-dose systemic immunosuppressive medications (e.g., a one-time dose of dexamethasone for nausea or chronic use of ≤ 10 mg/day of prednisone or dose equivalent corticosteroid) may be enrolled in the study after discussion with and approval by the Sponsor. The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) is allowed.
  14. Patient has not recovered (to Grade ≤ 1) from previous anti-cancer therapy-induced adverse events (AEs).

    Note: Patients with Grade ≤ 2 neuropathy, Grade ≤ 2 alopecia, or Grade ≤ 2 fatigue are an exception to this criterion and may qualify for the study.

  15. Patient has not recovered adequately from AEs or complications from any major surgery prior to starting therapy. Major surgical procedures, other than for diagnosis, within 4 weeks prior to initiation of study treatment
  16. Patient has a known to bevacizumab or dostarlimab components or .
  17. Patient is currently participating and receiving study treatment or has participated in a study of an agent and received study treatment or used an investigational device within 4 weeks of the first dose of treatment.
  18. Patient is considered a poor medical condition due to a serious, uncontrolled medical disorder, non-malignant systemic disease, or active infection requiring systemic therapy. Specific examples include, but are not limited to, active, non-infectious pneumonitis; uncontrolled ventricular arrhythmia; recent (within 90 days) myocardial infarction; uncontrolled major seizure disorder; unstable spinal cord compression; superior vena cava syndrome; or any psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study (including obtaining informed consent).
  19. Patients with known history of non-infectious pneumonitis that required steroids or has current pneumonitis
  20. Use of any of the following immunomodulatory agents within 28 days prior to the first dose of study drug:

    • Interferons
    • Interleukins
    • Note: Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster, yellow fever, rabies, BCG, and typhoid vaccine. mRNA and adenoviral-based COVID-19 vaccines are considered non-live and are not exclusionary. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed as other killed vaccines, if done at least 2 weeks prior the first dose of study drug; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed.
  21. Patient who are pregnant or lactating, or plan to become pregnant or lactate during the expected duration of the study, from screening through 180 days after the last dose of study drug.
Terms in these criteria, in plain language(33)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
199 participants (actual)

Study arms

  • Experimental
    Group A

    Dostarlimab monotherapy

    Drug: Dostarlimab

  • Experimental
    Group B

    Dostarlimab + Bevacizumab combination therapy

    Drug: Dostarlimab · Drug: Bevacizumab

  • Active comparator
    Group C

    General chemotherapy (one of Pegylated liposomal doxorubicin, Doxorubicin, Paclitaxel, and Gemcitabine)

    Drug: Doxorubicin · Drug: Gemcitabine · Drug: Paclitaxel · Drug: Pegylated liposomal doxorubicin

Interventions

06

What researchers measure

Primary outcomes

  1. Progression Free Survival

    The time from the date of randomization until first documentation of disease progression, as determined by investigator assessment based on RECIST 1.1, or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 48 months

Secondary outcomes

  1. Objective Response Rate

    the proportion of patients who have best overall response of either complete response (CR) or partial response (PR), as investigator assessment based on RECIST 1.1

    Time frame: Up to approximately 48 months

  2. Disease control rate

    the proportion of patients who have best overall response of CR, PR, or stable disease (SD) by investigator assessment per RECIST 1.1 . SD must be achieved at ≥ 7 weeks after randomization to be considered best overall response.

    Time frame: Up to approximately 48 months

  3. Clinical benefit rate

    the proportion of patients who have best overall response of CR, PR, or stable disease (SD) by investigator assessment per RECIST 1.1 . (duration of SD ≥ 23 weeks after randomization)

    Time frame: Up to approximately 48 months

  4. Progression Free Survival 2

    the time from initial randomization to the second objective disease progression (ie, after the first subsequent therapy) or death.

    Time frame: Up to approximately 72 months

  5. Overall survival

    the time from the date of randomization until death due to any cause

    Time frame: Up to approximately 72 months

  6. Duration of Response Rate

    Measured from the time of initial response until documented tumor progression.

    Time frame: Up to approximately 48 months

  7. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    Assessed by CTCAE v5.0 (by investigators).

    Time frame: Up to approximately 72 months

  8. Time to first and second Subsequent Treatment

    the time from the date of randomization to date of the first and second subsequent anticancer therapy or death.

    Time frame: Up to approximately 72 months

  9. Response rate of subsequent therapies

    the proportion of patients who have best overall response of either complete response (CR) or partial response (PR), as investigator assessment based on RECIST 1.1

    Time frame: Up to approximately 72 months

Other outcomes

  1. Disease-related or Treatment-related Biomarkers

    Translational research including NGS as well as MMRd, MSI-H, PD1/L1, TMB, Immune signature, and Tie-2.

    Time frame: At the end of study, Up to approximately 72 months

  2. Comparison of RECIST1.1 and i-RECIST assessment

    By comparing RECIST 1.1 and iRECIST, evaluate the accuracy of iRECIST for assessing the therapeutic efficacy of ICIs.

    Time frame: Throughout duration of study, Up to 48 months

07

Study locations

27 sites
08

References and documents

Publications

  • Lee JY, Tan D, Ray-Coquard I, Lee JB, Kim BG, Van Nieuwenhuysen E, Huang RY, Tse KY, Gonzalez-Martin A, Scott C, Hasegawa K, Wilkinson K, Yang EY, Lheureux S, Kristeleit R. Phase II randomized study of dostarlimab alone or with bevacizumab versus non-platinum chemotherapy in recurrent gynecological clear cell carcinoma (DOVE/APGOT-OV7/ENGOT-ov80). J Gynecol Oncol. 2025 Jan;36(1):e51. doi: 10.3802/jgo.2025.36.e51. Epub 2024 Dec 16. PubMed 39710508 ↗
09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Aug 2027, 43 months after the start.

Of 229 non-industry phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 80. This study's planned 43 months is below that.

Counting every sponsor, half of 345 studies reached it within 47 months; a quarter within 33 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2023
First posted
Sep 5, 2023
StartActual
Jan 22, 2024
Primary completionEst.
Aug 31, 2027
CompletionEst.
Dec 31, 2029
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 2, 2026
Enrollment
198 (estimated)→199 (actual)
Nov 18, 2026
Eligibility
2 inclusion criteria removed; 8 criteria edited, 7 added
What changed in the criteria
  • Added[Inclusion Criteria]
  • Edited-≥50% clear cell histology in case of mixed carcinoma
  • Added1-5 prior lines of therapies Notes: Patients can participate in the trial regardless of prior exposure to bevacizumab. The sponsor may limit the enrollment of patients with prior exposure to bevacizumab in order to ensure an appropriate representativeness (approximately 50%) of patients without prior exposure to bevacizumab.
  • AddedAvailability of Tumor tissue for translational research .
  • EditedAvailability of Tumor tissue for translational research . - A formalin-fixed paraffin-embedded (FFPE) tumor block(preferred) or at least 2023 slides (unstained, freshly cut, serial sections) must be submitted.
  • Edited-Confirmed with at least one lesion with location accessible to safely biopsy per the clinical judgement of the investigator Note: If mandatory biopsies cannot be performed as per investigator's clinical judgement, discussion and agreement between investigator and Sponsor are required.
  • EditedPatient of childbearing potential must agree to use a highly effective method of contraception with their partners starting from time of consent through 180 days after the last dose of study treatment. Note: Abstinence is acceptable if this is the established and preferred contraception for the patient (Information must be captured appropriately within the site's source documents).
  • AddedNote: Abstinence is acceptable if this is the established and preferred contraception for the patient (Information must be captured appropriately within the site's source documents).
  • Added[Exclusion Criteria]
  • AddedPatients are to be excluded from the study if they meet any of the following criteria:
  • AddedPatient has known uncontrolled central nervous system metastases, carcinomatosis meningitis, or both.
  • EditedPatient has known uncontrolled central nervous system metastases, carcinomatosis meningitis, or both. Note: Patients with previously treated brain metastases may participate provided they are stable (without evidence of disease progression by imaging [using the identical imaging modality for each assessment, either MRI or CT scan] for at least 4 weeks prior to the first dose of study treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and have not been using steroids for at least 7 days prior to study treatment. Carcinomatous meningitis precludes a patient from study participation regardless of clinical stability.
  • EditedParticipants with positive hepatitis C antibody due to prior resolved disease can be enrolled only if a confirmatory negative hepatitis C RNA polymerase chain reaction is obtained. Hepatitis C participants may be eligible if they both have completed curative therapy and have a hepatitis C viral load <!-- Not Allowed Tag Filtered --><quantifiable limit.
  • EditedPatient has an active autoimmune disease that has required systemic treatment in the past 2 years. Replacement therapy is not considered a form of systemic therapy (ege.g., thyroid hormone or insulin).
  • EditedPatient has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of systemic immunosuppressive therapy within 7 days prior to the first dose of study treatment. Patients who have received acute and>/or low-dose systemic immunosuppressive medications (e.g,., a one-time dose of dexamethasone for nausea or chronic use of ≤ 10 mg/day of prednisone or dose equivalent corticosteroid) may be enrolled in the study after discussion with and approval by the Sponsor. The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) is allowed.
Inclusion criteria
  • Removed1-5 prior lines of therapies
  • RemovedConfirmed with at least one lesion with location accessible to safely biopsy per the clinical judgement of the investigator
Nov 18, 2026
Show all 2 updates
  1. Nov 18, 2026
    Enrollment 198 (estimated)→199 (actual)
    Eligibility 2 inclusion criteria removed; 8 criteria edited, 7 added
    What changed in the criteria
    • Added[Inclusion Criteria]
    • Edited-≥50% clear cell histology in case of mixed carcinoma
    • Added1-5 prior lines of therapies Notes: Patients can participate in the trial regardless of prior exposure to bevacizumab. The sponsor may limit the enrollment of patients with prior exposure to bevacizumab in order to ensure an appropriate representativeness (approximately 50%) of patients without prior exposure to bevacizumab.
    • AddedAvailability of Tumor tissue for translational research .
    • EditedAvailability of Tumor tissue for translational research . - A formalin-fixed paraffin-embedded (FFPE) tumor block(preferred) or at least 2023 slides (unstained, freshly cut, serial sections) must be submitted.
    • Edited-Confirmed with at least one lesion with location accessible to safely biopsy per the clinical judgement of the investigator Note: If mandatory biopsies cannot be performed as per investigator's clinical judgement, discussion and agreement between investigator and Sponsor are required.
    • EditedPatient of childbearing potential must agree to use a highly effective method of contraception with their partners starting from time of consent through 180 days after the last dose of study treatment. Note: Abstinence is acceptable if this is the established and preferred contraception for the patient (Information must be captured appropriately within the site's source documents).
    • AddedNote: Abstinence is acceptable if this is the established and preferred contraception for the patient (Information must be captured appropriately within the site's source documents).
    • Added[Exclusion Criteria]
    • AddedPatients are to be excluded from the study if they meet any of the following criteria:
    • AddedPatient has known uncontrolled central nervous system metastases, carcinomatosis meningitis, or both.
    • EditedPatient has known uncontrolled central nervous system metastases, carcinomatosis meningitis, or both. Note: Patients with previously treated brain metastases may participate provided they are stable (without evidence of disease progression by imaging [using the identical imaging modality for each assessment, either MRI or CT scan] for at least 4 weeks prior to the first dose of study treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and have not been using steroids for at least 7 days prior to study treatment. Carcinomatous meningitis precludes a patient from study participation regardless of clinical stability.
    • EditedParticipants with positive hepatitis C antibody due to prior resolved disease can be enrolled only if a confirmatory negative hepatitis C RNA polymerase chain reaction is obtained. Hepatitis C participants may be eligible if they both have completed curative therapy and have a hepatitis C viral load <!-- Not Allowed Tag Filtered --><quantifiable limit.
    • EditedPatient has an active autoimmune disease that has required systemic treatment in the past 2 years. Replacement therapy is not considered a form of systemic therapy (ege.g., thyroid hormone or insulin).
    • EditedPatient has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of systemic immunosuppressive therapy within 7 days prior to the first dose of study treatment. Patients who have received acute and>/or low-dose systemic immunosuppressive medications (e.g,., a one-time dose of dexamethasone for nausea or chronic use of ≤ 10 mg/day of prednisone or dose equivalent corticosteroid) may be enrolled in the study after discussion with and approval by the Sponsor. The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) is allowed.
    Inclusion criteria
    • Removed1-5 prior lines of therapies
    • RemovedConfirmed with at least one lesion with location accessible to safely biopsy per the clinical judgement of the investigator
    + 1 other change: verification date
  2. Nov 2, 2026
    Recruiting→Active, not recruiting
    + 2 other changes: contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06023862
Lead sponsor
Yonsei University
Collaborators
GlaxoSmithKline
Responsible party
JUNGYUN LEE (Professor, Yonsei University) — Principal investigator
First posted
Sep 5, 2023
Start date
Jan 22, 2024
Primary completion
Aug 31, 2027 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Nov 18, 2026

Study contacts

JUNGYUN LEE, Ph.D.
principal investigator · Severance Hospital, Yonsei University Health System

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dostarlimab · Bevacizumab

Start the discussion